Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in children with moderate to severe atopic dermatitis (Start Up Japan)
NCT06701331Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Dec 2024; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06701331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701331.